UC Researches Depression in Women
With women twice as likely to suffer from depression as men, researchers continue to ask why they are so vulnerable and to seek new medications to treat the widespread problem.
Researchers at the UC Medical Center Women's Health Research Program, one of few groups in the country that focus on causes and treatments of disorders that predominately affect women, are investigating a new medication that shows promise in alleviating the effects of depression.
Women suffering from depression are invited to participate in the study, during which they will receive free study-related medication and evaluations.
Typical symptoms of depression include feeling sad or down, losing interest in usual activities, feelings of guilt, worthlessness, or hopelessness, and sleeplessness or lack of energy.
Lesley M. Arnold, MD, director of the Women's Health Research Program, says although it's not certain why women are more prone to depression than men, there is some evidence of a genetic link.
Dr. Arnold, an associate professor of psychiatry, says women "may inherit a propensity to become depressed in response to stress."
There's also evidence, Dr. Arnold says, that healthy women produce less serotonin, an important neurotransmitter involved in mood regulation, than men.
"We suspect that stress depletes serotonin," Dr. Arnold says, "so if you start with lower levels, as women do, serotonin could be depleted more easily, making women more susceptible to depression."
Depression is just one of the program's research interests. Investigators are also studying fibromyalgia, a chronic pain condition that is much more common in women than in men. Fibromyalgia is associated with fatigue, sleep disturbance and several other symptoms.
UC's Women's Health Research Program is a national leader in fibromyalgia research and has an ongoing fibromyalgia clinical trial and a genetic study.
Women interested in participating in the depression or fibromyalgia studies are invited to call 513-558-WHRP for more information. All inquiries will be confidential.
Tags
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.